慢性疼痛患者阿片类药物使用与睡眠呼吸障碍
过去二十年慢性疼痛阿片类药物使用显著增加,伴随死亡率和不良反应上升。中重度睡眠呼吸障碍(包括中枢性和阻塞性睡眠呼吸暂停)在慢性疼痛患者中高流行,是阿片相关死亡的重要贡献因素。尽管有循证治疗,疼痛门诊对睡眠呼吸障碍评估不足。本文综述阿片与睡眠呼吸障碍的相互作用、患病率及预测因素,并提供临床评估建议。
要点
- 慢性疼痛阿片治疗患者中重度睡眠呼吸障碍高发,增加死亡风险。
- 疼痛门诊应常规评估阿片治疗患者的睡眠呼吸障碍风险。
- 早期识别可促进阿片减量或气道正压治疗,改善生活质量。
核心结论
- 慢性疼痛阿片治疗患者中重度睡眠呼吸障碍高流行,临床应加强评估以早期干预。
研究设计与样本
- 综述,总结阿片与睡眠呼吸障碍相互作用的证据及患病率与预测因素。
主要发现
- 慢性疼痛患者中中重度睡眠呼吸障碍(包括中枢性和阻塞性睡眠呼吸暂停)患病率高。
- 睡眠呼吸障碍是阿片相关死亡的重要贡献因素。
- 疼痛门诊对睡眠呼吸障碍评估不频繁。
临床怎么用
- 对阿片治疗的慢性疼痛患者评估中重度睡眠呼吸障碍风险。
- 识别后尽早采用阿片停用或气道正压治疗等干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The past two decades has seen a substantial rise in the use of opioids for chronic pain, along with opioid-related mortality and adverse effects. A contributor to opioid-associated mortality is the high prevalence of moderate/severe sleep-disordered breathing, including central sleep apnea and obstructive sleep apnea, in patients with chronic pain. Although evidence-based treatments are available for sleep-disordered breathing, patients are not frequently assessed for sleep-disordered breathing in pain clinics. To aid healthcare providers in this area of clinical uncertainty, we present evidence on the interaction between opioids and sleep-disordered breathing, and the prevalence and predictive factors for sleep-disordered breathing in patients on opioids for chronic pain. We provide recommendations on how to evaluate patients on opioids for risk of moderate/severe sleep-disordered breathing in clinical care, which could lead to earlier use of therapeutic interventions for opioid-associated sleep-disordered breathing, such as opioid cessation or positive airway pressure therapy. This would improve quality of life and well-being of patients with chronic pain.
引用
- Selvanathan J, Peng PWH, Wong J, et al. Sleep-disordered breathing in patients on opioids for chronic pain. Reg Anesth Pain Med. 2020. PMID: 32928994. doi:10.1136/rapm-2020-101540
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。